Anika Therapeutics
ANIK
120 hedge funds and large institutions have $340M invested in Anika Therapeutics in 2024 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 43 increasing their positions, 41 reducing their positions, and 11 closing their positions.
193% more call options, than puts
Call options by funds: $469K | Put options by funds: $160K
27% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 11
13% more capital invested
Capital invested by funds: $300M → $340M (+$40.2M)
3% more funds holding
Funds holding: 117 → 120 (+3)
1.04% more ownership
Funds ownership: 90.51% → 91.54% (+1%)
5% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 41
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CP
Caligan Partners
New York
|
+$8.58M |
| 2 |
Morgan Stanley
New York
|
+$5.24M |
| 3 |
BlackRock
New York
|
+$4.29M |
| 4 |
MIM
Meros Investment Management
Dallas,
Texas
|
+$2.91M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$2.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$5.12M |
| 2 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
-$4.77M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$3.61M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$2.48M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$2.02M |
ANIK Hedge Fund Activity: Q1 2024 in Review
120 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q1 2024, worth a combined $340M — up 13% from $300M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new ANIK positions and 11 closed out — a net gain of 3 holders — while 43 added to existing stakes and 41 trimmed.
The largest buyer was Caligan Partners, adding an estimated $8.58M. The largest seller was Millennium Management, cutting an estimated $5.12M.
- 120 institutional investors held Anika Therapeutics (ANIK) as of Q1 2024, up from 117 in Q4 2023.
- Funds reported $340M of Anika Therapeutics stock for Q1 2024, up 13% quarter-over-quarter.
- 14 funds opened new Anika Therapeutics positions in Q1 2024 and 11 closed out, a net change of +3 holders.
- The largest Anika Therapeutics buyer in Q1 2024 was Caligan Partners, an estimated $8.58M added.
- The largest Anika Therapeutics seller in Q1 2024 was Millennium Management, an estimated $5.12M sold.
Based on aggregated 13F filings for Q1 2024.